No, dapagliflozin should NOT be initiated in a patient currently experiencing DKA
Dapagliflozin must be immediately discontinued if DKA is present and should only be restarted after complete resolution of the ketoacidosis and when the patient is clinically stable with resumed oral intake. 1
Critical Safety Considerations
Why SGLT2 Inhibitors Are Contraindicated During Active DKA
The FDA drug label explicitly states that if ketoacidosis is suspected, you must:
- Discontinue dapagliflozin immediately
- Promptly evaluate and treat the ketoacidosis
- Monitor for complete resolution before considering restart
- Only resume when the patient is clinically stable and has resumed oral intake 1
SGLT2 inhibitors like dapagliflozin significantly increase the risk of ketoacidosis, particularly euglycemic DKA where blood glucose may be deceptively normal (often <250 mg/dL) 2, 1. This creates a dangerous situation where the medication perpetuates the very condition you're trying to treat.
The Mechanism Problem
Dapagliflozin causes persistent glucosuria that can continue for 3 days after discontinuation (and in some cases up to 2 weeks) 1. Case reports document:
- Persistent ketonuria and glucosuria lasting 8-11 days after stopping dapagliflozin 3
- Relapse of euglycemic DKA occurring days after initial treatment due to ongoing drug effects 3, 4
- Fatal outcomes in patients with type 2 diabetes using SGLT2 inhibitors during ketoacidosis 1
When Can Dapagliflozin Be Considered?
After DKA Resolution
Only restart dapagliflozin when ALL of the following are met:
- Complete resolution of ketoacidosis (negative or trace ketones, normalized pH and anion gap)
- Patient is clinically stable
- Patient has resumed normal oral intake
- Precipitating factors have been addressed 1
Risk Mitigation for Future Use
If restarting after DKA resolution, implement these safeguards 2, 5:
Patient education on "sick day rules":
- Hold dapagliflozin during acute illness, nausea, vomiting, diarrhea, or reduced oral intake
- Discontinue 3 days before any planned surgery 6, 5
- Maintain at least low-dose insulin (never stop insulin completely in insulin-requiring patients)
- Monitor for ketoacidosis symptoms: nausea, vomiting, abdominal pain, malaise, shortness of breath
High-risk situations requiring dapagliflozin discontinuation:
- Acute febrile illness
- Reduced caloric intake or ketogenic diet
- Surgery or invasive procedures
- Volume depletion
- Alcohol abuse
- Under-insulinization 1
Common Pitfall
The most dangerous error is assuming normal blood glucose excludes DKA in patients on SGLT2 inhibitors. Euglycemic DKA is the hallmark complication of this drug class—you must assess for ketoacidosis regardless of presenting blood glucose levels if metabolic acidosis symptoms are present 2, 1.
Special Populations at Highest Risk
Patients requiring insulin are at particular risk for SGLT2 inhibitor-associated ketoacidosis 2. Type 2 diabetes and pancreatic disorders (history of pancreatitis or pancreatic surgery) are additional risk factors 1.